Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 4, 2024

Primary Completion Date

September 20, 2024

Study Completion Date

May 28, 2025

Conditions
HER2-negative Metastatic Breast Cancer
Interventions
DRUG

Gemcitabine, Vinorelbine, or Eribulin

Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06533722 - Adaptive Therapy for Post-Second-Line Advanced Breast Cancer | Biotech Hunter | Biotech Hunter